Focus: Lumen Bioscience is a Seattle-based biotech company leveraging biologics to address infectious diseases, ophthalmology, and neurology. Founded in 2023, the company operates at Series C+ stage with 51-200 employees.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
High-risk, high-reward opportunity best suited for biotech professionals seeking early-stage impact and willing to tolerate clinical development uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lumen Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lumen Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo